Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.

The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 significantly up-regulated the steady-state mRNA and protein levels of Notch1 in p53 wild-type (OCI, SKW6.4) but not in p53 deleted (HL-60) or p53 mutated (BJAB) leukemic cell lines. A direct demonstration that Notch1 was a transcriptional target of p53 in leukemic cells was obtained in experiments carried out with siRNA for p53. Moreover, inhibition of Notch1 expression by using Notch1 specific siRNA significantly increased cytotoxicity in p53 wild-type leukemic cells. Of note, Nutlin-3 up-regulated Notch1 expression also in primary p53 wild-type B-chronic lymphocytic leukemia (B-CLL) cells and the combined use of Nutlin-3 plus pharmacological γ-secretase inhibitors of the Notch signaling, showed a synergistic cytotoxicity in both p53 wild-type leukemic cell lines and primary B-CLL. A potential drawback of γ-secretase inhibitors was their ability to enhance osteoclastic maturation of normal circulating preosteoclasts induced by RANKL+M-CSF. Notwithstanding, Nutlin-3 completely suppressed osteoclastogenesis irrespective of the presence of γ-secretase inhibitors. Taken together, these data indicate that the p53-dependent up-regulation of Notch1 in response to Nutlin-3 represents an anti-apoptotic feedback mechanism able to restrain the potential therapeutic efficacy of Nutlin-3 in hematological malignancies. Therefore, therapeutic combinations of Nutlin-3+γ-secretase inhibitors might potentiate the cytotoxicity of Nutlin-3 in p53 wild-type leukemic cells.

[1]  Ying-hua Jin,et al.  Caspase 3-mediated Cleavage of p21 WAF1/CIP1 Associated with the Cyclin A-Cyclin-dependent Kinase 2 Complex Is a Prerequisite for Apoptosis in SK-HEP-1 Cells* , 2000, The Journal of Biological Chemistry.

[2]  F. Alimirah,et al.  Restoration of p53 expression in human cancer cell lines upregulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress. , 2007, Neoplasia.

[3]  L. Vassilev,et al.  Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells , 2007, Leukemia.

[4]  D. Dittmer,et al.  Functional p53 Signaling in Kaposi's Sarcoma-Associated Herpesvirus Lymphomas: Implications for Therapy , 2006, Journal of Virology.

[5]  L. Reiniger,et al.  Activity of the Notch‐signalling Pathway in Circulating Human Chronic Lymphocytic Leukaemia Cells , 2007, Scandinavian journal of immunology.

[6]  Chin-Tong Ong,et al.  NOTCH1 Regulates Osteoclastogenesis Directly in Osteoclast Precursors and Indirectly via Osteoblast Lineage Cells* , 2008, Journal of Biological Chemistry.

[7]  M. Dettke,et al.  Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. , 2002, Blood.

[8]  M. Nakao,et al.  Transcriptional Blockade Induces p53-dependent Apoptosis Associated with Translocation of p53 to Mitochondria* , 2005, Journal of Biological Chemistry.

[9]  Taku Sato,et al.  Gamma-secretase inhibitors suppress the growth of leukemia and lymphoma cells. , 2007, Oncology reports.

[10]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[11]  S. Salati,et al.  Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects , 2008, Current opinion in hematology.

[12]  S. de Vos,et al.  Modeling Notch Signaling in Normal and Neoplastic Hematopoiesis: Global Gene Expression Profiling in Response to Activated Notch Expression , 2007, Stem cells.

[13]  M. Kaminski,et al.  Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. , 2007, Blood.

[14]  M. Vitale,et al.  Thrombopoietin enhances the alpha IIb beta 3-dependent adhesion of megakaryocytic cells to fibrinogen or fibronectin through PI 3 kinase. , 1997, Blood.

[15]  S. Pavey,et al.  Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. , 2001, Molecular pharmacology.

[16]  T. Park,et al.  Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation , 2007, Cell Death and Differentiation.

[17]  P. Secchiero,et al.  TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. , 2004, Blood.

[18]  S. Hayashi,et al.  Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. , 2003, Blood.

[19]  P. Ojala,et al.  p53 Reactivation Kills KSHV Lymphomas Efficiently In Vitro and In Vivo: New Hope for Treating Aggressive Viral Lymphomas , 2007, Cell cycle.

[20]  P. Secchiero,et al.  Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. , 2007, Current drug metabolism.

[21]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[22]  S. Leach,et al.  Notch in malignancy. , 2003, Cancer treatment and research.

[23]  Hong Yang,et al.  Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. , 2005, Cancer research.

[24]  M. Hilgarth,et al.  Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2 , 2005, Leukemia.

[25]  I. Screpanti,et al.  Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. , 2009, Blood.

[26]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[27]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[28]  P. Secchiero,et al.  TRAIL inhibits osteoclastic differentiation by counteracting RANKL‐dependent p27Kip1 accumulation in pre‐osteoclast precursors , 2008, Journal of cellular physiology.

[29]  G. Nilsson,et al.  Distinct and regulated expression of Notch receptors in hematopoietic lineages and during myeloid differentiation , 2001, European journal of immunology.

[30]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[31]  L. Vassilev,et al.  Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. , 2005, Blood.

[32]  R. Fanin,et al.  Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) , 2006 .

[33]  M. Fujita,et al.  Regulation of Notch1 Gene Expression by p53 in Epithelial Cells , 2007, Molecular and Cellular Biology.

[34]  L. Jeffrey Medeiros,et al.  Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma , 2007, Clinical Cancer Research.

[35]  P. Secchiero,et al.  The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. , 2008, Current pharmaceutical design.

[36]  P. Secchiero,et al.  Tumour necrosis factor‐related apoptosis‐inducing ligand sequentially activates pro‐survival and pro‐apoptotic pathways in SK‐N‐MC neuronal cells , 2003, Journal of neurochemistry.

[37]  T. Golde,et al.  TCR-mediated Notch signaling regulates proliferation and IFN-gamma production in peripheral T cells. , 2003, Journal of immunology.

[38]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[39]  L. Espinosa,et al.  The notch pathway positively regulates programmed cell death during erythroid differentiation , 2007, Leukemia.

[40]  Y. Okamoto,et al.  SurveyorTM nuclease-based detection of p53 gene mutations in haematological malignancy , 2007, Annals of clinical biochemistry.

[41]  Marina Konopleva,et al.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. , 2006, Blood.

[42]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[43]  Sathish Kumar Mungamuri,et al.  Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. , 2006, Cancer research.

[44]  T. Honjo,et al.  Conservation of the biochemical mechanisms of signal transduction among mammalian Notch family members , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Gabriel Pons,et al.  MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.

[46]  B. Dörken,et al.  Notch signaling in leukemias and lymphomas. , 2008, Current molecular medicine.

[47]  L. Vassilev,et al.  p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. , 2008, Blood.